喘的凝血阴影:一项元分析揭示了血栓性滴答定时炸弹
Kaiwen Zheng1, Yuling Zhao2, Jiayi Li2
1School of Clinical Medicine, Shandong Second Medical University, Weifang, Shandong, China.
概括
喘显著增加了静脉血栓栓塞 (VTE) 的风险,包括肺栓塞 (PE) 和深静脉血栓塞 (DVT). 这种关联在亚洲人群和队列研究中尤为明显.
科学领域:
- 肺部医学 肺部医学
- 心血管研究研究心血管研究
- 流行病学 流行病学
背景情况:
- 喘是一种慢性呼吸道疾病,影响着全世界数以百万计的人.
- 静脉血栓塞栓症 (VTE),包括肺栓塞 (PE) 和深静脉血栓症 (DVT),代表着严重的健康负担.
- 喘和VTE风险之间的潜在联系需要进行系统的调查.
研究的目的:
- 系统地评估喘与发展VTE的风险之间的关联.
- 量化患有喘的个体中PE和DVT的风险增加.
- 探索这种关联在不同研究设计和地理区域的变化.
主要方法:
- 在PubMed,Embase,Web of Science和Cochrane图书馆进行了全面的文献搜索,截至2025年5月.
- 包括观察性研究 (队列,病例控制,横截面) 报告喘-VTE关联.
- 进行了元分析,使用报告的几率比率 (OR) 或危险比率及其95%置信区间.
主要成果:
- 喘与静脉瘤风险增加有显著的关联.
- 患有喘的患者患PE的几率高出2.41倍 (OR=2.41),患DVT的几率高出1.56倍 (OR=1.56).
- 整体VTE风险是1.61倍高 (OR=1.61),在队列研究 (OR=4.21) 和亚洲人群 (OR=3.19) 中观察到的最强的关联.
结论:
- 喘是VTE,PE和DVT的重要危险因素.
- 这种关联在队列研究和亚洲人群中尤为明显.
- 需要进一步的研究来阐明潜在的机制和喘管理对血栓形成风险的潜在影响.
相关概念视频
01:26Asthma-II: Pathophysiology and Classification
4.0K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
4.0K
01:24Asthma-III: Symptoms and Complications
3.2K
Asthma, a common chronic respiratory condition, is classified considering the frequency and severity of symptoms alongside lung function impairment. Understanding this classification is essential for appropriate treatment and management. Here's a detailed look at the classification of asthma and its clinical features and complications:
Classification of Asthma
Classification of Asthma
3.2K
01:29Asthma-I: Introduction
3.3K
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
3.3K
01:20Asthma: Pathogenesis and Management
1.2K
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.2K
01:30Asthma-IV: Diagnostic and Management
3.0K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.0K
01:19Antiasthma Drugs: Leukotriene Modifiers
1.7K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
1.7K